NCT00982345

Brain Imaging of Quetiapine Response in Anxious Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Indiana University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain.

Detailed description

This study will measure the activity and connectivity in different parts of the brain, while the patients are seeing some pictures, using Magnetic Resonance Imaging (MRI) scan. For this study three MRI scans will be conducted. One before the patient begins on any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment with seroquel.

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	quetiapine (Seroquel XR)	Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.

Timeline

• Start date: 2009-03-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-09-23
• Last updated: 2016-09-30
• Results posted: 2016-09-30

Locations

1 site across 1 country: United States